Hims & Hers Health, Inc. (NYSE: HIMS)

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS).

On June 23, 2025, Novo Nordisk announced that it was terminating its partnership with Hims & Hers, disclosing that the Company had “failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of ‘personalization’ and are disseminating deceptive marketing that put patient safety at risk,” and that “the ‘semaglutide’ active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies” may contain “unsafe and illicit foreign ingredients.”

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period including alleged misrepresentations regarding the Company’s business, operations, and prospects, and in particular, regarding the business relationship between the Company and Novo Nordisk, violating federal securities laws. Recently, the Court presiding over the case denied the Company’s motion to dismiss, allowing the case to move forward.

KSF’s investigation is focusing on whether Hims & Hers’ officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Hims & Hers shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or fill out the form on this page.